Author | Dylan Fisher


Nivolumab/Ipilimumab Combo Approved for Advanced RCC

April 19, 2018

ByDylan Fisher

In a pivotal trial, combination of nivolumab and ipilimumab yielded improvement in OS and ORR of poor-risk RCC patients.

Brentuximab Vedotin Approved for Classical HL

April 10, 2018

ByDylan Fisher

The FDA has approved brentuximab vedotin (Adcetris) to treat adults with previously untreated stage III or IV cHL, in combination with chemotherapy.

FDA Expands Blinatumomab Approval for ALL to Include MRD

April 03, 2018

ByDylan Fisher

The US Food and Drug Administration has approved blinatumomab (Blincyto) for patients in remission from B-cell precursor ALL with MRD.